Patents by Inventor Taishan Hu

Taishan Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210355122
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 6, 2018
    Publication date: November 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian Dey, Taishan Hu, Haixia Liu, Hong Shen, Zhiwei Zhang, Wei Zhu
  • Patent number: 11168086
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 9, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Xingchun Han, Buyu Kou, Hong Shen, Shixiang Yan, Zhisen Zhang
  • Publication number: 20210309636
    Abstract: Indazole derivatives represented by formula (I) or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof are provided. A preparation method of indazole derivatives represented by formula (I) and a method of use of the indazole derivatives as therapeutic agents is also provided.
    Type: Application
    Filed: August 15, 2019
    Publication date: October 7, 2021
    Inventors: Yongping LU, Cheng YE, Wenjian QIAN, Taishan HU, Lei CHEN
  • Publication number: 20210277021
    Abstract: Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as an angiotensin II type 2 receptor (AT2R) antagonist, wherein definitions of substituent groups in the general formula (I) are the same as definitions in the description.
    Type: Application
    Filed: June 18, 2019
    Publication date: September 9, 2021
    Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Yanghui GUO, Xiangui HUANG, Weiwei LIAO, Lichen MENG, Taishan HU, Lei CHEN, Guoping JIANG
  • Publication number: 20210269451
    Abstract: The present invention relates to compounds of formula (I), a b (I), wherein R1 to R4 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 2, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: HAIXIA LIU, HONG SHEN, WEI ZHU, TAISHAN HU, ZHISEN ZHANG, ZHIWEI ZHANG, FABIAN DEY, XIAOQING WANG
  • Patent number: 11098080
    Abstract: The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: August 24, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Julien Beignet, Konrad Bleicher, Bernhard Fasching, Hans Hilpert, Taishan Hu, Dwight MacDonald, Stephen Jackson, Sabine Kolczewski, Carsten Kroll, Adrian Schaeublin, Hong Shen, Theodor Stoll, Helmut Thomas, Amal Wahhab, Claudia Zampaloni
  • Patent number: 10781206
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R5 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: September 22, 2020
    Assignee: HOFFMANN LA-ROCHE INC.
    Inventors: Taishan Hu, Hong Shen, Xingchun Han
  • Patent number: 10683299
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: June 16, 2020
    Assignee: HOFFMANN LA ROCHE INC.
    Inventors: Xingchun Han, Xianfeng Lin, Hong Shen, Taishan Hu, Zhisen Zhang
  • Publication number: 20200181156
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Buyu Kou, Haixia Liu, Zhisen Zhang, Zheng Zhou
  • Patent number: 10604527
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: March 31, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Haixia Liu
  • Publication number: 20200062753
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen, Houguang Shi, Shixiang Yan, Weixing Zhang, Zhisen Zhang, Mingwei Zhou, Wei Zhu
  • Patent number: 10562905
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: February 18, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Buyu Kou, Haixia Liu, Zhisen Zhang, Zheng Zhou
  • Publication number: 20190322670
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: January 14, 2019
    Publication date: October 24, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Buyu Kou, Haixia Liu, Zhisen Zhang, Zheng Zhou
  • Publication number: 20190321440
    Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.
    Type: Application
    Filed: April 19, 2019
    Publication date: October 24, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Konrad BLEICHER, Daniella CHEANG, Patrick DI GIORGIO, Taishan HU, Christian JENNY, Patrizio MATTEI, Petra SCHMITZ, Theodor STOLL
  • Publication number: 20190300569
    Abstract: The present invention provides compounds of formula (I) wherein X, L1 and R1 to R10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.
    Type: Application
    Filed: March 19, 2019
    Publication date: October 3, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Daniella Cheang, Patrick Di Giorgio, Taishan Hu, Patrizio Mattei, Petra Schmitz, Theodor Stoll
  • Patent number: 10428069
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: October 1, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen, Houguang Shi, Shixiang Yan, Weixing Zhang, Zhisen Zhang, Mingwei Zhou, Wei Zhu
  • Publication number: 20190248786
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R5 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: January 14, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Hong Shen, Xingchun Han
  • Publication number: 20190248792
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: January 14, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xingchun Han, Xianfeng Lin, Hong Shen, Taishan Hu, Zhisen Zhang
  • Publication number: 20190185476
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 20, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Haixia Liu
  • Publication number: 20180370969
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen, Houguang Shi, Shixiang Yan, Weixing Zhang, Zhisen Zhang, Mingwei Zhou, Wei Zhu